Nivolumab plus Ipilimumab in MSI-High Metastatic Colorectal Cancer
1. Progression-free survival at 12 months was 79% with nivolumab/ipilimumab vs 21% with chemotherapy, and 24-month PFS was 72% and...
Early Ramucirumab/Paclitaxel vs Continuation of First-line Chemotherapy in Advanced HER2-negative Gastric/Gastroesophageal Cancer
1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group with HR...
Radiotherapy with cetuximab or durvalumab for advanced HNSCC
1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33...
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
1. The median progression-free survival was 15.0 months in the inavolisib and 7.3 months in the placebo group, with HR...
Cabozantinib In Advanced Neuroendocrine Tumors
1. Progression-free survival had a hazard ratio of 0.38 (extrapancreatic NETs) and 0.23 (pancreatic NETs) for those treated with cabozantinib...
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse...
Ponsegromab for the Treatment of Cancer Cachexia
1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in...
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar in both...
Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma
1. The median progression-free survival in the metastasis-directed therapy arm was 10.3 months vs 2.5 months in the control arm...
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy
1. When comparing corticosteroid peak dose for immunosuppression for anti–PD-1 plus anti–CTLA-4–related adverse events, the HR for OS was 1.66...